T&L Biotechnology

Recombinant Human IFN-α2b Protein

Catalog Number: GMP-TL763

Gene Name Synonym :IFNA2,IFNA2b,alpha-2a interferon,IFNA,IFN-alpha-2,IFN-alphaA,INFA2,interferon alpha 2b, interferon alpha A, interferon alpha-2, Interferon alpha-A,interferon, alpha 2.

Construction: A DNA sequence encoding human IFN-α2b (NP_P01563) was expressed with his tag at the C terminal.

Source::Human

Expression Host: HEK293 cell

QC Testing Purity: > 95 % as determined by SDS-PAGE

Bio Activity: The ED50 as determined by an anti-viral assay using bovine kidney MDBK cells is less than 5pg/ml, corresponding to a specific activity of >1.0×108IU/mg.

Endotoxin: < 1EU per ug of the protein as determined by the LAL method.

Molecular Mass: The recombinant human IFN-λ1 contains 179 amino acids with a predicted molecular weight of 21 kD.

Formulation: Lyophilized from sterile PBS, pH 7.4. Normally 6 % - 8 % mannitol are added as protectants before lyophilization.

Stability & Storage: Samples are stable for up to 24 months from date of receipt at 4 ℃and the dissolved liquid can be stored at -20℃ for 6-12 months.Avoid repeated freeze-thaw cycles.

Protein Description

Human IFN-α2a and-α2b represent allelic variants of the same gene. IFN-α2a and -α2b have a lysine and an arginine at position 23 of the mature protein, respectively . Human IFN-α2a and -α2b are the only IFN-α subtypes with an O-glycosylation site (on Thr106) .Human IFN-α2b is induced in peripheral blood mononuclear cells (PBMCs) upon incubation with CpG-oligonucleotides and in plasmacytoid dendritic cells upon incubation with CpG-oligonucleotides or imiquimod .This subtype of IFN-α is classified as an intermediate/strong ISG inducer [3,4], with strong anti-viral activity against influenza A virus. Similar to IFN-α 1 and α -8 subtypes, human IFN-α2 expression occurs early post-infection with Sendai virus in vitro, regardless of the viral multiplicity of infection (MOI) and may deliver a ‘priming’ signal to neighboring cells. Recombinant human IFN-α2 is the only clinically-approved IFN-α subtype and both IFN-α2a and -α2b are used to treat chronic hepatitis B or C, hairy cell leukemia and other forms of cancer.

References

1. Sonya A MacParland, Christopher P Corkum, Christopher Burgess, Sylwia Karwowska, Werner Kroll, Tomasz I Michalak. Differential expression of interferon alpha inducible genes in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus and healthy donors. Int Immunopharmacol. 2015 Apr;25(2):545-52.

2. Thomas F Gajewski, Leticia Corrales. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr;26(2):175-8.

3. John M Kirkwood, Lisa H Butterfield, Ahmad A Tarhini, Hassane Zarour, Pawel Kalinski, Soldano Ferrone. Immunotherapy of cancer in 2012. CA Cancer J Clin. Sep-Oct 2012;62(5):309-35.

Trial dosage: A customer can apply for up to five samples a year (the actual trial dosage is determined by telephone or email communication).
Scope of use: Samples are limited to testing and research purposes.
Cost: Free for samples, customer is responsible for shipping and handling charges, reference cost is $50 in the US, €60 in the EU, and $50 in other countries.
How to apply: You can apply by telephone or by email (the email application should specify the sample name, item number, contact person, telephone number, consignee address, etc.).